SRR1085782
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.441
- TNFA_SIGNALING_VIA_NFKB+0.344
- IL6_JAK_STAT3_SIGNALING+0.317
- IL2_STAT5_SIGNALING+0.310
- ANDROGEN_RESPONSE+0.299
- INFLAMMATORY_RESPONSE+0.287
- PROTEIN_SECRETION+0.276
- ALLOGRAFT_REJECTION+0.275
- MTORC1_SIGNALING+0.268
- BILE_ACID_METABOLISM+0.265
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.496
- PANCREAS_BETA_CELLS-0.419
- MYC_TARGETS_V2-0.327
- KRAS_SIGNALING_DN-0.217
- NOTCH_SIGNALING-0.179
- E2F_TARGETS-0.158
- G2M_CHECKPOINT-0.151
- OXIDATIVE_PHOSPHORYLATION-0.091
- UV_RESPONSE_DN-0.081
- SPERMATOGENESIS-0.059
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1458595 | GTEX | — | 0.927 |
| 2 | SRR1413768 | GTEX | — | 0.892 |
| 3 | SRR1333694 | GTEX | — | 0.889 |
| 4 | SRR1402882 | GTEX | — | 0.875 |
| 5 | SRR1446828 | GTEX | — | 0.865 |
| 6 | SRR1486304 | GTEX | — | 0.839 |
| 7 | SRR660895 | GTEX | — | 0.839 |
| 8 | SRR1429244 | GTEX | — | 0.833 |
| 9 | SRR1402840 | GTEX | — | 0.833 |
| 10 | SRR1350525 | GTEX | — | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.441 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.344 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.317 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.299 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.287 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.276 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.275 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.268 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.265 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.252 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.244 | Inavolisib | — uncovered |
| PEROXISOME | 0.233 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.228 | Inavolisib | — uncovered |
| APOPTOSIS | 0.225 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.219 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.213 | Idelalisib | — uncovered |
| COAGULATION | 0.212 | Binimetinib | — uncovered |
| COMPLEMENT | 0.207 | Inavolisib | — uncovered |